In Vivo Respiratory Disease and PK/PD Models

Contact Us

Highly experienced in vivo team and integrated support teams

Multiple validated small animal models with option for customization

Specialized Aerosol Technology team to support the inhalation dose route

Start your discovery efficacy and early safety respiratory studies right with our lead optimization in vivo models supported by integrated teams  focusing on in vitro aerosol safetybiomarkersdiscovery bioanalysis, histology and special pathology and cell and molecular sciences. Our scientific leaders provide valuable insights based on decades of experience and are dedicated to delivering high-quality data to meet your timelines.

Key capabilities:

  • Multiple small animal models validated with clinically relevant positive control, plus bespoke model development upon request
  • BSL2 containment facilities to support pathogen (Bacterial, fungal and viral) work
  • Expertise in invasive (Flexivent, forced manouvres) and non-invasive (Plethysmography) lung function
  • Automated technology for in-life data capture including cough counting and performing Total and differential cell counts
  • Aerosol Technology team to support the inhalation dose route for novel compounds (aerosol and dry powder) and inflammatory challenges
  • Microbiology support for pathogen inoculum preparation and tissue burden end points
  • Immunoassay and immunotoxicology department to support a comprehensive local and systemic biomarker end points, including cytokine multiplexing and single plate ELISA’s, flow cytometry and other plate based assays

Respiratory Efficacy Disease PK/PD Models

Note: Many of our posters are gated to protect proprietary and sensitive content. You'll be asked to create a free login to access the poster.

Animal model  Species  Clinically Relevant Positive Control and MOA of Test Compounds Tested Disease Target Therapeutic Indication Publication
Ovalbumin sensitisation and challenge model  (airway challenge)  Brown Norway Rat, mouse, guinea pig Steroids (systemic and inhaled), dexamethasone, budesonide, fluticasone propionate, PI3Kinase Multiple anti-inflammatory targets Asthma Alterations in airway mechanics, inflammatory biomarkers and lung histopathology in a rat model of allergen –induced airway inflammation 
Ovalbumin sensitisation and challenge model  (nasal upper airway challenge)  Mouse Steroid ( dexamethasone) Multiple anti-inflammatory targets Rhinitis  
House dust mite chronic model  Mouse IL-5 antibodies, prednisolone, PDE4 (roflumilast) inhaled steroids (budesonide) Multiple anti-inflammatory targets Asthma Assessment of the time course of chronic inflammation in the Murine house dust mite model
IL-13 PK/PD goblet cell hyperplasia model  Rat - IL-13 pathways for mucolytics Cystic fibrosis  
LPS neutrophil chemotaxis PK/PD model ( inhaled and systemic) Rat, mouse, guinea pig  Steroids, PDE4 antagonists, P38 MAP Kinases  Neutrophil chemotaxis COPD, neutrophilic  asthma Acute markers of neutrophilic lung infiltration in the nonhuman primate LPS model
Inhaled LPS + FMLP PK/PD model  Rat  AZD9668,Sivelestat (NE inhibitors) Neutrophil elastase COPD   
Acute 5, 12 and 17  day Tobacco smoke model (steroid insensitive) Mouse PDE4 (Roflumilast), inhaled PDE4 (GSK256066) Multiple anti-inflammatory COPD Efficacy of an inhaled PDE4 inhibitor, GSK256066, delivered by a novel dry powder preclinical inhalation delivery system in the acute cigarette smoke induced pulmonary inflammation model
Human neutrophil elastase lung haemorrhage model  Rat  AZD9668, Sivelestat (NE inhibitors) Neutrophil elastase COPD, bronchiectasis  
Anti-tussive model  Guinea pig codeine Anti-tussives Chronic Cough/ COPD, lung fibrosis)  
Bronchoconstriction models  Guinea pig Beta agonists (LABA) (e.g. Formoterol), Long acting muscarinic agonists (LAMA) e.g. tiotropium and dual pharmacophores muscarinic antagonists/beta agonist (MABA)  e.g Batefenterol Bronchodilators (LABA, LAMA & MABA) COPD (asthma)  
Bleomycin induced lung fibrosis model  Rat , mouse Pirfenidone, Nintedanib  Multiple targets for lung fibrosis Pulmonary Fibrosis (IPF)

Changes in airway platelet population and morphology in a Murine model of lung fibrosis


Correlation of Nintedanib efficacy on fibrotic lesion deposition and lung function within a rat IPF model


Nintedanib attenuates lung function decline in a Bleomycin-induced rat model of pulmonary fibrosis


Repeat low doses of Bleomycin induces progressive changes in Murine lung mechanics associated with the development of pulmonary fibrosis

Chlorine induced lung injury  Rat  N/A ( Orphan drug indication) Chemical lung injury  Chemical exposure   
H1N1 viral pulmonary inflammation model  Mouse/Ferret Anti-infectives (Oseltamivir “Tamiflu”) Anti-infectives or viral induce lung injury  Infectious disease/lung injury/COPD exacerbations  Assessment of viral load and time course of pulmonary inflammation in a Murine model of H1N1 (PR8) influenza virus infection
Pseudomonas aeruginosa lung injury and lung infection model  Mouse Anti-infectives antibiotics/anti-inflammatory/mucolytis Anti-infectives or bacteria induce lung injury  Infectious disease/Cystic Fibrosis/COPD exacerbations  
Allergic Aspergillus  Mouse Anti-infectives (anti-fungal) Anti-fungals or allergy induce lung injury  Allergic Aspergillosis  

Looking for more disease models? Check out our oncology models and all other pharmacology models

Ready to schedule your next study?

Contact Us